Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes

Abstract

Epithelial ovarian cancer is a highly heterogeneous disease and remains the most lethal gynaecological malignancy in the Western world. Therapeutic approaches need to account for inter-patient and intra-tumoural heterogeneity and detailed characterization of in vitro models representing the different histological and molecular ovarian cancer subtypes is critical to enable reliable preclinical testing. There are approximately 100 publicly available ovarian cancer cell lines but their cellular and molecular characteristics are largely undescribed. We have characterized 39 ovarian cancer cell lines under uniform conditions for growth characteristics, mRNA/microRNA expression, exon sequencing, drug response for clinically-relevant therapeutics and collated all available information on the original clinical features and site of origin. We tested for statistical associations between the cellular and molecular features of the lines and clinical features. Of the 39 ovarian cancer cell lines, 14 were assigned as high-grade serous, four serous-type, one low-grade serous and 20 non-serous type. Three morphological subtypes: Epithelial (n = 21), Round (n = 7) and Spindle (n = 12) were identified that showed distinct biological and molecular characteristics, including overexpression of cell movement and migration-associated genes in the Spindle subtype. Comparison with the original clinical data showed association of the spindle-like tumours with metastasis, advanced stage, suboptimal debulking and poor prognosis. In addition, the expression profiles of Spindle, Round and Epithelial morphologies clustered with the previously described C1-stromal, C5-mesenchymal and C4 ovarian subtype expression profiles respectively. Comprehensive profiling of 39 ovarian cancer cell lines under controlled, uniform conditions demonstrates clinically relevant cellular and genomic characteristics. This data provides a rational basis for selecting models to develop specific treatment approaches for histological and molecular subtypes of ovarian cancer.

The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets

“…Accordingly, precision oncology depends on the ability to functionally interrogate preclinical models capturing the molecular heterogeneity observed in patients. While collections of cancer cells derived from multiple tumor types have been previously described 1,2,4 , comprehensive databases of cells derived from single tumour lineages are much less common 16,31 . To capture the clinical heterogeneity of CRCs, we assembled a collection of 151 cell lines.…”

Design, synthesis and biological evaluation of thiosemicarbazones, hydrazinobenzothiazoles and arylhydrazones as anticancer agents with a potential to overcome multidrug resistance

“…The ovarian carcinoma cell line A2780 and the uterine sarcoma cell line MES-SA were compared to their doxorubicin-selected counterparts A2780adr and MES-SA/Dx5, respectively [57][58][59], while the cervix carcinoma cell line KB-3-1 was compared to the vinblastine-selected line KB-V1 [60,61]. In addition, toxicity of selected active derivatives M A N U S C R I P T…”

Effect of IL-6 and IL-8 on the expression of the complement activation inhibitors MAC-inhibitory protein and decay-accelerating factor in ovarian cancer A2780 cells

“…The largest effect in Wang et al (14) study was observed after 120 h incubation with IL-6, IL-8 or both. Additionally, the cell lines used were different in origin, genetic profile and clinical stage, so the influence of IL-6 and IL-8 may be different (15).…”